Metaxalone submicron

Drug Profile

Metaxalone submicron

Alternative Names: IC-1201; ICE-1201; Submicron metaxalone

Latest Information Update: 09 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Muscle relaxants; Oxazolidinones; Small molecules
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Musculoskeletal disorders

Most Recent Events

  • 09 Feb 2017 Metaxalone submicron is still in phase I development for Musculoskeletal disorders in USA (iCeutica pipeline, February 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-disorders in USA (PO, Tablet)
  • 12 Sep 2013 Top-line pharmacokinetics & adverse events data from a phase I trial in Healthy volunteers released by iCeutica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top